Biopharma | January 07, 2026
Medera doses final patient in high-dose HFpEF gene therapy trial
Heart failure affects an estimated 64.3 million people worldwide
Heart failure affects an estimated 64.3 million people worldwide
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
India’s pharmaceutical sector stands at a pivotal inflection point
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The accelerated review covers WCK 5222 for multiple critical infections
Subscribe To Our Newsletter & Stay Updated
